Anatara Lifesciences LtdASX: ANR

Investor Update

· Issued by Anatara Lifesciences Ltd

Filed with ASX · · 29 pages · English

The Company remains well positioned for the launch of Detach™, its non-antibiotic treatment for gastrointestinal disease. Initially focused on pigs, launch is expected in 2017 and follows the Anatara’s application in October to the Australian Pesticides and Veterinary Medicines Authority (APVMA) for approval to sell and market Detach™. Chairman and CEO, Dr Mel Bridges commented, “With our APVMA su

Anatara Lifesciences Ltd on 6ix

Earlier from Anatara Lifesciences

Later from Anatara Lifesciences

All Anatara Lifesciences news releases